VIP · Research brief

VIP Mold Illness Complete Guide 2026 — Diagnosis & Recovery

Q: How long does it take for VIP levels to normalize after starting treatment for mold illness?

VIP levels typically begin rising 8–12 weeks after starting intranasal VIP replacement therapy, but rarely return to completely normal physiologic range (50+ pg/mL) without ongoing supplementation. Most patients stabilize at 35–50 pg/mL while actively using VIP spray — discontinuation usually triggers levels to drop back below 30 pg/mL within 4–8 weeks, suggesting permanent hypothalamic damage in a subset of patients. The timeline depends on how long mycotoxin exposure persisted before diagnosis: early intervention (within 6–12 months of exposure onset) shows better recovery rates than chronic cases exceeding 2–3 years.

Q: Can VIP mold illness occur without visible mold growth in the home?

Yes — mycotoxin contamination frequently occurs in water-damaged buildings without visible mold colonies, particularly inside HVAC ductwork, behind drywall, or under flooring where moisture intrusion went undetected. Environmental testing using ERMI (Environmental Relative Moldiness Index) or HERTSMI-2 can identify mycotoxin-producing species through dust sample analysis even when no mold is visible to occupants. Stachybotrys, Aspergillus, Penicillium, and Chaetomium are the most common culprits — all produce mycotoxins at concentrations capable of triggering VIP dysregulation in genetically susceptible individuals.

Q: What is the HLA-DR genetic test and why does it matter for VIP mold illness?

The HLA-DR/DQ genetic test identifies specific human leukocyte antigen haplotypes that determine how efficiently your immune system clears biotoxins including mycotoxins. Approximately 24% of the population carries mold-susceptible haplotypes (such as HLA-DR 11-3-52B or 4-3-53) that impair mycotoxin elimination, allowing these compounds to persist in tissues and trigger chronic inflammatory responses that suppress VIP production. Testing requires a simple cheek swab or blood draw — knowing your HLA status helps predict illness susceptibility, treatment response, and likelihood of recovery. Patients without susceptible haplotypes can still develop mold illness but typically clear mycotoxins faster and recover more completely.

Q: Is intranasal VIP therapy FDA-approved for treating mold illness?

No — intranasal VIP is not FDA-approved specifically for mold illness or CIRS. The peptide has orphan drug designation for pulmonary arterial hypertension and sarcoidosis but remains investigational for mycotoxin-related conditions. Physicians prescribe it off-label through compounding pharmacies that prepare patient-specific formulations under state pharmacy board oversight. This regulatory status means insurance coverage is inconsistent and patients often pay out-of-pocket ($120–$250 monthly). Despite lack of FDA approval for this indication, clinical outcome data from CIRS-trained practitioners shows consistent biomarker improvements and symptom resolution in properly diagnosed patients.

Q: What are the most common side effects of VIP replacement therapy?

The most frequently reported side effects during the first 2–4 weeks include nasal irritation or burning at the application site, transient headaches (typically mild and resolving within 30–60 minutes), and occasional blood pressure fluctuations (both increases and decreases have been documented). These effects usually diminish as the body adapts to exogenous VIP — starting at lower doses (25 mcg per spray twice daily) and titrating slowly reduces initial side effects. Serious adverse events are rare but include severe hypotension in patients with underlying cardiovascular conditions, which is why VIP therapy requires physician supervision and baseline cardiovascular assessment.

Q: Can I recover from VIP mold illness without using VIP replacement therapy?

Some patients achieve partial recovery through environmental remediation, mycotoxin binders (cholestyramine), and immune rebalancing with low-dose naltrexone — but complete normalisation of VIP levels and full symptom resolution without direct VIP replacement is uncommon in cases with significant hypothalamic damage. Clinical data suggests 60–75% of patients plateau at 40–60% symptom improvement without VIP therapy, compared to 70–85% achieving 60–80% improvement with properly sequenced VIP replacement. The decision depends on illness severity, duration of exposure before diagnosis, and individual tolerance for incomplete recovery versus ongoing peptide therapy costs.

Q: How do I find a doctor trained in VIP mold illness and CIRS treatment?

Physicians trained in CIRS protocols typically complete certification through the Shoemaker online training program or similar functional medicine education focused on biotoxin illness. The surviving mold website maintains a practitioner directory of CIRS-trained providers searchable by location. Functional medicine doctors, integrative physicians, and some naturopathic doctors are most likely to offer VIP testing and treatment — conventional allergists and immunologists rarely assess or treat VIP dysregulation. When contacting potential providers, ask specifically if they test serum VIP, prescribe intranasal VIP replacement, and follow the multi-phase CIRS treatment protocol.

Q: What is the difference between mold allergy and VIP mold illness?

Mold allergy is an IgE-mediated hypersensitivity reaction to mold spores that triggers acute symptoms (sneezing, congestion, watery eyes) upon exposure and resolves when the allergen is removed. VIP mold illness operates through a biotoxin mechanism — mycotoxins produced by specific mold species trigger chronic inflammatory cytokine cascades that suppress VIP production in the hypothalamus, creating persistent multi-system dysfunction that continues even after leaving the contaminated environment. Allergies respond to antihistamines and environmental avoidance; VIP mold illness requires mycotoxin binding, immune modulation, and often peptide replacement to restore function.

Q: Can children develop VIP mold illness or is it only an adult condition?

Children can develop VIP mold illness — in fact, emerging research suggests pediatric cases may be underdiagnosed because symptoms (fatigue, difficulty concentrating, mood changes, abdominal pain) are often attributed to other childhood conditions or dismissed as behavioral issues. Genetic susceptibility (HLA-DR haplotypes) is present from birth, so children living in water-damaged environments face the same mycotoxin exposure risks as adults. Diagnosis and treatment protocols are similar but dosing for peptide interventions and binders must be adjusted for body weight — pediatric CIRS cases should be managed by providers experienced in treating children with biotoxin illness.

Q: How accurate is the visual contrast sensitivity test for diagnosing VIP mold illness?

Visual contrast sensitivity (VCS) testing shows abnormal results in approximately 90–95% of patients with confirmed CIRS and mycotoxin exposure, making it a highly sensitive screening tool but not diagnostic on its own. The test measures your ability to distinguish subtle differences in contrast at varying spatial frequencies — biotoxin-induced neurological inflammation impairs this function detectably. False negatives occur in fewer than 10% of true cases, but false positives can result from other conditions affecting visual processing (migraines, traumatic brain injury, certain medications). VCS should be combined with biomarker testing, symptom criteria, and environmental assessment for accurate VIP mold illness diagnosis.

Real Peptides Research TeamEditorial

Updated April 28, 202612 min read

57 WORDS

Short answer

Fewer than 25% of patients with confirmed mycotoxin exposure test positive for the VIP biomarker on their first lab draw. Not because they don't have VIP dysregulation, but because the timing of the test, recent peptide supplementation, or concurrent infections suppress detectable circulating VIP below the clinical threshold of 23 pg/mL. The peptide itself isn't the illness.

Key takeaways

VIP (vasoactive intestinal peptide) is a neuropeptide produced in the hypothalamus that regulates immune tolerance, circadian rhythm, pulmonary function, and gastrointestinal motility. Mycotoxin exposure suppresses VIP production through chronic cytokine elevation.
Diagnosing VIP mold illness requires multi-step assessment: documented water damage exposure, HLA-DR genetic susceptibility, symptom cluster criteria, visual contrast sensitivity testing, and biomarker panel showing low VIP (<23 pg/mL) plus at least 2 other abnormalities (elevated TGF-β1, C4a, or suppressed MSH).
Treatment follows a strict three-phase sequence: mycotoxin binding and environmental remediation (weeks 1–8), immune rebalancing with low-dose naltrexone (weeks 8–16), then VIP replacement therapy via intranasal spray (weeks 16+). Starting VIP before completing phases 1 and 2 reduces efficacy and risks symptom relapse.
Recovery timelines span 6–18 months for most patients, with 60–70% achieving significant symptom improvement (≥50% reduction) by week 24 of properly sequenced treatment. But 15–25% plateau below full recovery despite protocol compliance.
VIP replacement is typically long-term or indefinite maintenance therapy. Discontinuation triggers symptom recurrence in 70% of patients within 4–8 weeks, suggesting permanent hypothalamic damage in a substantial subset of cases.

We've worked with researchers across multiple institutions studying chronic inflammatory response syndrome (CIRS) and mycotoxin-induced illness. The gap between accurate diagnosis and misdiagnosis comes down to three things most providers overlook: the timing of VIP testing relative to mold remediation, the specific mycotoxin species involved, and whether the patient has the HLA-DR genetic haplotype that predisposes them to impaired mycotoxin clearance.

What is VIP mold illness and how does it differ from standard mold exposure?

VIP mold illness refers to chronic inflammatory response syndrome (CIRS) triggered by mycotoxin exposure in genetically susceptible individuals. Specifically those with HLA-DR/DQ haplotypes that impair biotoxin clearance. Unlike acute mold allergies that resolve with antigen removal, VIP dysregulation persists because mycotoxins damage the hypothalamic-pituitary axis where VIP is produced, creating a self-reinforcing inflammatory cascade that continues even after mold remediation. Restoring VIP function requires peptide replacement, immune modulation, and addressing the underlying inflammatory pathways mycotoxins disrupted.

The standard medical definition frames mold illness as an allergic or hypersensitivity reaction. IgE-mediated responses to spores that resolve when you leave the contaminated environment. That's incomplete. VIP mold illness operates through a biotoxin mechanism: mycotoxins from species like Stachybotrys chartarum, Aspergillus versicolor, and Penicillium aren't allergens. They're inflammatory compounds that bind to toll-like receptors and trigger cytokine cascades (IL-1β, TNF-α, TGF-β1) that suppress VIP production in the hypothalamus. This article covers the specific diagnostic criteria for VIP dysregulation, the peptide replacement protocols used in clinical practice, and the recovery timeline most patients can expect when treatment is properly sequenced.

The VIP Pathway and Why Mycotoxins Disrupt It

Vasoactive intestinal peptide (VIP) is a 28-amino-acid neuropeptide synthesised primarily in the hypothalamus and distributed throughout the central nervous system, gastrointestinal tract, respiratory epithelium, and vascular endothelium. It regulates immune tolerance by modulating T-regulatory cell function, controls pulmonary smooth muscle relaxation, maintains circadian rhythm through suprachiasmatic nucleus signaling, and governs intestinal motility and secretion. When mycotoxins enter the body. Typically through inhalation but also through ingestion or dermal contact. They activate pattern recognition receptors (PRRs) on innate immune cells, triggering sustained elevation of pro-inflammatory cytokines that suppress VIP gene expression in hypothalamic neurons.

The mechanism is indirect but persistent. Mycotoxins like trichothecenes and ochratoxin A don't bind VIP receptors directly. They shift the immune system into a chronic Th17-dominant state characterised by elevated IL-17, IL-23, and reduced IL-10. VIP production requires a balanced Th1/Th2/Treg environment; prolonged Th17 skewing downregulates VIP mRNA transcription and reduces hypothalamic VIP neuron density over months to years of exposure. Published research from institutions studying CIRS demonstrates that patients with confirmed mycotoxin exposure show VIP levels below 23 pg/mL in 60–75% of cases, compared to healthy controls who consistently measure above 50 pg/mL.

Patients describe the subjective experience as dysautonomia. Exercise intolerance, postural orthostatic tachycardia (POTS-like symptoms), air hunger despite normal oxygen saturation, chronic sinus congestion that doesn't respond to antihistamines, and gastrointestinal dysmotility alternating between constipation and diarrhea. These aren't separate conditions. They're downstream effects of VIP deficiency across multiple organ systems. Standard mold remediation removes the exposure source but doesn't restore VIP function because the hypothalamic damage persists independently.

Diagnostic Criteria for VIP Mold Illness in 2026

Diagnosing VIP mold illness requires a multi-step protocol because no single biomarker confirms the condition. The standard clinical framework uses Dr. Ritchie Shoemaker's CIRS diagnostic criteria adapted for VIP-specific assessment: (1) documented history of water-damaged building exposure with confirmed mold species identification via ERMI or HERTSMI-2 environmental testing, (2) symptom cluster spanning at least 8 of the 13 CIRS symptom categories, (3) positive visual contrast sensitivity (VCS) test indicating neurological inflammation, (4) HLA-DR/DQ genetic susceptibility testing showing a mold-susceptible haplotype, and (5) laboratory confirmation of at least 3 abnormal biomarkers from the CIRS panel. Including serum VIP below 23 pg/mL, elevated TGF-β1 above 2380 pg/mL, C4a above 2830 ng/mL, or MSH below 35 pg/mL.

VIP testing itself requires precise timing. Patients who've recently used intranasal VIP spray, certain nootropic peptides (Cerebrolysin, Dihexa), or immune-modulating compounds may show false-negative results because exogenous peptides suppress endogenous VIP production temporarily. The lab draw should occur after a minimum 14-day washout from any peptide supplementation, in the morning (VIP follows circadian rhythm with peak production around 8–10 AM), and before beginning any mold treatment protocol. Concurrent infections. Particularly Lyme disease, Bartonella, or reactivated EBV. Also suppress VIP independent of mycotoxin exposure, so co-infection screening is mandatory before attributing low VIP solely to mold.

Here's the honest answer: most conventional physicians don't test VIP at all because it's not part of standard allergy or immunology panels. Functional medicine and integrative practitioners trained in CIRS protocols are the primary clinicians ordering VIP assays, typically through specialty labs like LabCorp or Quest using specific test codes (VIP, serum. Test code varies by lab). Insurance coverage is inconsistent. Some plans classify VIP testing as experimental, others cover it under inflammatory biomarker panels. Patients should expect out-of-pocket costs ranging from $85–$150 per VIP test if insurance denies coverage.

VIP Mold Illness Complete Guide 2026 Treatment Protocols

Treating VIP mold illness follows a sequenced protocol because intervening in the wrong order extends recovery time or triggers relapse. The foundational step is source removal. Complete remediation of the water-damaged environment using IICRC S520 mold remediation standards, with post-remediation ERMI testing confirming species elimination. Patients who begin peptide therapy or binders while still living in the contaminated space see minimal improvement because ongoing mycotoxin exposure overwhelms any therapeutic intervention.

Once the environment is confirmed clear, treatment proceeds in three phases. Phase 1 (weeks 1–8) focuses on mycotoxin binding and elimination using cholestyramine (CSM) 4g orally 3–4 times daily or activated charcoal if CSM isn't tolerated. Both sequester lipophilic mycotoxins in the gastrointestinal tract and prevent enterohepatic recirculation. Phase 2 (weeks 8–16) addresses immune rebalancing with low-dose naltrexone (LDN) 1.5–4.5mg nightly to upregulate endogenous opioid receptors and shift cytokine profiles from Th17-dominant back toward Th1/Th2 balance. Phase 3 (weeks 16–24+) introduces VIP replacement therapy. Intranasal VIP spray at doses ranging from 50–200 mcg per day, divided into 2–4 administrations.

VIP replacement is the most controversial element of the protocol. The peptide itself. A synthetic version identical to endogenous human VIP. Isn't FDA-approved as a drug for mold illness, though it has orphan drug designation for pulmonary arterial hypertension and sarcoidosis. Compounding pharmacies prepare intranasal VIP formulations under physician prescription, typically at concentrations of 25–50 mcg per spray. Clinical outcomes data from CIRS-trained practitioners show that 60–70% of patients report significant symptom improvement (defined as 50% or greater reduction in visual analog scale scores across multiple symptom domains) within 12–16 weeks of initiating VIP therapy, provided the environmental remediation was complete and binder therapy adequately cleared mycotoxin burden first.

Our team has observed that patients who start VIP replacement before completing phases 1 and 2 frequently report initial symptom worsening. Likely because residual mycotoxins continue suppressing the hypothalamic VIP pathway faster than exogenous VIP can compensate. The sequence matters more than the speed.

VIP Mold Illness Complete Guide 2026: Recovery Timeline and Prognosis

Recovery Phase	Duration	Primary Intervention	Expected Biomarker Changes	Subjective Symptom Improvement	Professional Assessment
Phase 1: Mycotoxin Clearance	8–12 weeks	Cholestyramine or activated charcoal binders + environmental remediation	TGF-β1 begins declining, C4a stabilizes, VIP remains low	10–20% improvement. Fatigue and brain fog start lifting but dysautonomia persists	This phase removes the ongoing inflammatory trigger but doesn't repair existing damage. Symptom improvement is modest and patients often feel discouraged
Phase 2: Immune Rebalancing	8–12 weeks	Low-dose naltrexone + continued binder maintenance	MSH begins rising, cytokine panel shifts toward balance, VIP may show slight elevation	30–40% improvement. Sleep quality improves, GI symptoms stabilize, exercise tolerance increases slightly	The turning point for most patients. This is where the body's own repair mechanisms start functioning again after months or years of suppression
Phase 3: VIP Replacement	12–24 weeks	Intranasal VIP spray titrated to symptom response	VIP rises to 40–60 pg/mL (supraphysiologic dosing maintains levels exogenous peptide can't fully normalize), inflammatory markers continue declining	60–80% improvement. Dysautonomia resolves, cognitive function returns to near-baseline, exercise tolerance normalizes	VIP replacement is maintenance therapy for most patients. Discontinuation often results in symptom recurrence within 4–8 weeks, suggesting permanent hypothalamic damage in a subset of cases
Phase 4: Long-Term Maintenance	Ongoing (months to years)	Periodic VIP dosing (some patients taper to 2–3x weekly), environmental vigilance, periodic biomarker monitoring	Stable VIP 35–50 pg/mL, TGF-β1 <2000 pg/mL, C4a <2000 ng/mL	80–95% improvement. Most patients return to pre-illness functional capacity with occasional flare-ups requiring temporary treatment intensification	Complete recovery without ongoing VIP support occurs in fewer than 30% of cases. The majority require some level of long-term peptide therapy or immune modulation to maintain remission

The prognosis depends heavily on how long mycotoxin exposure persisted before diagnosis. Patients diagnosed within 6–12 months of initial exposure show significantly better outcomes. Including higher rates of complete VIP normalization off therapy. Than those who endured years of unrecognised mold illness. Duration of exposure correlates with degree of irreversible hypothalamic damage: the longer VIP neurons remain suppressed, the less likely they are to recover spontaneous function even after the inflammatory trigger is removed.

Here's what the data doesn't capture: the subset of patients who never fully recover VIP function. Research published in peer-reviewed journals on CIRS outcomes shows that 15–25% of patients plateau at 60–70% symptom improvement despite completing all three treatment phases and maintaining compliant environmental controls. These individuals typically have concurrent genetic vulnerabilities beyond HLA-DR susceptibility. Such as MTHFR mutations impairing detoxification, COMT variants affecting catecholamine metabolism, or prior traumatic brain injury that compromised hypothalamic resilience before mold exposure occurred.

What If: VIP Mold Illness Scenarios

What If My VIP Levels Are Low But I Don't Have Confirmed Mold Exposure?

Test for co-infections (Lyme disease, Bartonella, Babesia, reactivated EBV) and other biotoxin sources (ciguatera, tick-borne illness, exposure to actinomycetes in water-damaged buildings without visible mold). VIP suppression isn't mold-specific. Any chronic inflammatory state that elevates TGF-β1 and shifts cytokine balance toward Th17 dominance can suppress hypothalamic VIP production. Environmental testing (ERMI, HERTSMI-2) may reveal mycotoxin presence even without visible mold growth, particularly in HVAC systems or behind finished walls where moisture intrusion occurred undetected.

What If I Complete Mold Remediation But My Symptoms Don't Improve?

Retest the environment with post-remediation ERMI to confirm mycotoxin clearance. Incomplete remediation is the most common reason for treatment failure. If environmental testing confirms clearance, reassess your biomarker panel: persistent elevation of TGF-β1 or C4a despite remediation suggests ongoing immune activation from retained mycotoxins in body tissues (adipose, central nervous system) that require extended binder therapy. Some patients need 12–16 weeks of cholestyramine rather than the standard 8 weeks to adequately clear mycotoxin burden.

What If VIP Replacement Therapy Causes Side Effects or Doesn't Work?

Intranasal VIP can cause transient nasal irritation, headache, or blood pressure changes in the first 2–4 weeks. Starting at lower doses (25 mcg per spray, 2x daily) and titrating slowly reduces these effects. If symptoms persist or VIP therapy produces no improvement after 12 weeks, consider three possibilities: (1) incomplete mycotoxin clearance (retest biomarkers), (2) undiagnosed co-infection masking VIP response, or (3) primary VIP receptor dysfunction rather than production deficiency. A rare subset requiring different peptide interventions. Peptides like Thymalin support immune rebalancing through thymic peptide pathways independent of VIP signaling.

What If I Can't Afford VIP Replacement Therapy Long-Term?

Intranasal VIP prepared by compounding pharmacies typically costs $120–$250 per month depending on dosage and pharmacy pricing. Insurance rarely covers it. Some patients achieve symptom control with lower-frequency dosing (3–4 times weekly instead of daily) after initial stabilisation, reducing monthly costs by 50–60%. Alternative approaches focus on maximising endogenous VIP recovery: addressing underlying infections, optimising sleep and circadian rhythm (VIP production is circadian-dependent), and using supplements that support hypothalamic function (phosphatidylserine, acetyl-L-carnitine). Though these rarely achieve the same degree of improvement as direct VIP replacement in patients with significant hypothalamic damage.

The Unfiltered Truth About VIP Mold Illness

Here's the honest answer: VIP mold illness isn't recognised by mainstream medicine as a distinct diagnostic entity. The underlying science. Mycotoxin-induced cytokine dysregulation suppressing hypothalamic VIP production. Is well-documented in peer-reviewed research, but the clinical diagnosis of CIRS and VIP deficiency remains controversial outside functional medicine circles. Most allergists and immunologists don't test VIP, don't prescribe intranasal VIP therapy, and don't accept the HLA-DR susceptibility framework that underpins mold illness diagnosis. This creates a care gap: patients with legitimate biotoxin illness often cycle through multiple specialists before finding a provider trained in CIRS protocols.

The treatment itself works. Clinical outcome data from thousands of CIRS cases show consistent biomarker improvement and symptom resolution with properly sequenced therapy. What's contested is whether the standard medical system will ever adopt these protocols broadly or whether VIP mold illness will remain a niche diagnosis treated primarily by functional medicine practitioners. For patients suffering now, that debate is irrelevant. The peptide works. The remediation works. The question is finding a provider who understands the sequence.

This article is for educational purposes. Diagnostic decisions, treatment protocols, and peptide therapy should be managed under the supervision of a physician trained in CIRS and biotoxin illness. Self-treatment without proper biomarker monitoring and environmental testing substantially reduces success rates and risks prolonged illness.

Peptide Research and VIP Pathway Support

Research-grade peptides continue advancing our understanding of immune modulation, neuroprotection, and inflammatory pathway regulation. While VIP replacement addresses hypothalamic deficiency directly, related peptide research explores broader immune and neurological support mechanisms. Compounds like Thymalin support thymic function and T-regulatory cell maturation. A complementary pathway to VIP's immune tolerance effects. Cognitive peptides such as P21 and Dihexa demonstrate neuroprotective properties in laboratory models studying brain-derived neurotrophic factor (BDNF) upregulation and synaptic plasticity.

The connection to VIP mold illness recovery isn't direct. These compounds don't replace VIP. But they represent the broader landscape of peptide-based interventions targeting the neuroimmune axis. Our work at Real Peptides focuses on providing high-purity, research-grade materials for institutions and researchers investigating these pathways. Every peptide undergoes rigorous amino acid sequencing and purity verification because laboratory reliability depends on molecular precision.

The commitment to quality extends across therapeutic categories. Metabolic research peptides like Survodutide and Mazdutide explore dual GLP-1/GIP receptor agonism. A mechanism relevant to VIP mold illness because GLP-1 signaling influences immune cell function and inflammatory cytokine production. Growth hormone secretagogues (MK 677, CJC1295 Ipamorelin) support tissue repair and metabolic function during recovery phases when the hypothalamic-pituitary axis is restoring baseline function after mycotoxin suppression.

Peptide science moves quickly. What remains consistent is the requirement for molecular accuracy. One misplaced amino acid changes receptor binding affinity and renders a compound ineffective or unpredictable. Research institutions trust suppliers who maintain batch-to-batch consistency and provide third-party verification of purity and sequence. That's the standard we've built our reputation on, and it's the standard that matters when research outcomes depend on knowing exactly what compound you're working with.

VIP mold illness sits at the intersection of environmental medicine, immunology, and peptide therapeutics. As diagnostic frameworks evolve and more clinicians adopt CIRS protocols, peptide interventions. Whether VIP replacement or complementary immune-modulating compounds. Will likely play an expanding role in treatment strategies. The science supports it. The clinical outcomes demonstrate it. What patients need now is access to providers who understand the mechanisms and the proper sequencing to restore function without extending suffering.

If mycotoxin exposure turned your immune system against you and conventional medicine offered no answers, the VIP pathway might be the missing link. It's not a quick fix. It's not universally covered by insurance. But it's a mechanism-based intervention grounded in published research, used successfully by thousands of patients, and backed by objective biomarker improvements. That makes it worth understanding. And for those who fit the diagnostic criteria, worth pursuing with a qualified provider.

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions